Inecalcitol

Names

[ Name ]:
Inecalcitol

[Synonym ]:
(1R,3R,7E,14β,17β)-17-[(2R)-6-Hydroxy-6-methyl-4-heptyn-2-yl]-9,10-secoestra-5,7-diene-1,3-diol
1,3-Cyclohexanediol, 5-[(2E)-2-[(1R,3aR,7aR)-octahydro-1-[(1R)-5-hydroxy-1,5-dimethyl-3-hexyn-1-yl]-7a-methyl-4H-inden-4-ylidene]ethylidene]-, (1R,3R)-
UNII:05FZV98342
19-Nor-14-epi-23-yne-1,25 dihydroxyvitamin D3
TX 522
Inecalcitol
(7E)-(1R,3R,14R)-19-nor-23-yne-9,10-seco-5,7-cholestadiene-1,3,25-triol
MFCD09838524

Biological Activity

[Description]:

Inecalcitol (TX 522), a unique vitamin D3 analog, is an orally active vitamin D receptor (VDR) agonist with a Kd of 0.53 nM. Inecalcitol can induce cell apoptosis and has potent anticancer activities[1][2][3][4].

[Related Catalog]:

Signaling Pathways >> Apoptosis >> Apoptosis

Research Areas >> Cancer

Signaling Pathways >> Vitamin D Related >> VD/VDR

[Target]

Kd: 0.53 nM (vitamin D receptor (VDR))[2]

[In Vitro]

Inecalcitol (0.1-10 nM; 48 hours) treatment of LNCaP cells results in decreased expression of both protein and mRNA of Pim-1 in a dose-dependent manner. Inecalcitol (0.1-10 nM; 48 hours) also decreases ETV1 expression levels in a dose-dependent manner[1]. Inecalcitol (10-14 days) inhibits the growth of LNCaP and HL-60 cells with ED50 values of 4.0 nM and 0.28 nM, respectively[1]. Western Blot Analysis[1] Cell Line: LNCaP cells Concentration: 0.1 nM, 1 nM, 10 nM Incubation Time: 48 hours Result: Resulted in decreased expression of both protein and mRNA of Pim-1 in a dose-dependent manner.

[In Vivo]

Inecalcitol (1.3 mg/kg; i.p.; 3 times per week; for 42 days) inhibits androgen-responsive prostate cancer growth in vivo[1]. Pharmacokinetic studies show that plasma half-life of Inecalcitol (C57Bl/6J mice; 1.3 mg/kg; i.p.) is 18.3 minutes in mice[1]. Animal Model: Male BNX nu/nu mice (8 weeks of age) injected with LNCaP cells[1] Dosage: 1.3 mg/kg Administration: i.p.; 3 times per week; for 42 days Result: Inhibited androgen-responsive prostate cancer growth in vivo.

[References]

[1]. Ryoko Okamoto, et al. Inecalcitol, an analog of 1α,25(OH)(2) D(3) , induces growth arrest of androgen-dependent prostate cancer cells. Int J Cancer. 2012 May 15;130(10):2464-73.

[2]. L Verlinden, et al. Interaction of two novel 14-epivitamin D3 analogs with vitamin D3 receptor-retinoid X receptor heterodimers on vitamin D3 responsive elements. J Bone Miner Res. 2001 Apr;16(4):625-38.

[3]. Jacques Medioni, et al. Phase I safety and pharmacodynamic of inecalcitol, a novel VDR agonist with docetaxel in metastatic castration-resistant prostate cancer patients. Clin Cancer Res. 2014 Sep 1;20(17):4471-7.

[4]. Yingyu Ma, et al. Inecalcitol, an analog of 1,25D3, displays enhanced antitumor activity through the induction of apoptosis in a squamous cell carcinoma model system. Cell Cycle. 2013 Mar 1;12(5):743-52.

Chemical & Physical Properties

[ Density]:
1.2±0.1 g/cm3

[ Boiling Point ]:
568.6±50.0 °C at 760 mmHg

[ Molecular Formula ]:
C₂₆H₄₀O₃

[ Molecular Weight ]:
400.594

[ Flash Point ]:
244.6±24.7 °C

[ Exact Mass ]:
400.297760

[ PSA ]:
60.69000

[ LogP ]:
5.05

[ Vapour Pressure ]:
0.0±3.5 mmHg at 25°C

[ Index of Refraction ]:
1.627

Related Compounds

The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.